TRIPASS XR تري باس

 

Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartil. 2013;21:1145–1153.

Murray CJ et al. Disability-adjusted life years (DALYS) for 291 diseases and injuries in 21 regions, 1990–2010: a

systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2197–2223.

Petrenko A et al. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg.

2003;97:1108–1116.

Mika J et al. Importance of glial activation in neuropathic pain. Eur J Pharmacol. 2013;716:106–119.

Hameed H et al. The effect of morphine on glial cells as a potential therapeutic target for pharmacological

development of analgesic drugs. Curr Pain Headache Rep. 2010;14:96–104.

Thomas J et al. The relationship between opioid and immune signaling in the spinal cord. Handb Exp Pharmacol.

2015;227:207–238.

Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Ann Rev Med 2011;62:381–396.

Marchand S. Applied pain neurophysiology. In: Beaulieu P et al, eds. The Pharmacology of Pain. Seattle, WA:

IASP Press; 2010:3.

Hadjistavropoulos T et al. An interdisciplinary expert consensus statement on assessment of pain in older persons.

Clin J Pain. 2007;23(1, Suppl): S1–S43.

Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191.

MD Anderson Cancer Center. Symptom assessment tools. https://www.mdanderson.org/education-andresearch/departments-programs-and-labs/departments-and-divisions/symptom-research/symptomassessment-tools/brief-pain-inventory. Accessed June 13, 2016.

Finnerup NB et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.

Lancet Neurol. 2015:162–173.

Dworkin RH et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain.

2013;154:2249–2261.

Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev

Rheumatol. 2013;9(11):654–664.

Giamberardono MA et al. Myofascial pain syndromes and their elevation. Best Pract Res Clin Rheumatol.

2011;25:185–198.

Zhou Q, Verne GN. New insights into visceral hypersensitivity-clinical implications in IBS. Nat Rev Gastroenterol

Hepatol. 2011;8:349–355.

Argoff CE. Recent management advances in acute postoperative pain. Pain Pract. 2013;14(5):477–487.

Prabhakar A et al. Perioperative analgesia outcomes and strategies. Best Pract Res Clin Anaesthesiol.

2014;28:105–115.

Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert

Rev Neurother. 2009;9(5):723–744.

Cregg R et al. Persistent postsurgical pain. Curr Opin Support Palliat Care. 2013;7:144–152.

Shipton EA. The transition from acute to chronic post-surgical pain. Anaesth Intensive Care. 2011;39:824–836.

Chou R et al. Guidelines on the management of postoperative pain. J Pain. 2016;17(2):131–157.

Liao P et al. Postoperative complications in patients with obstructive sleep apnea: a retrospective matched cohort

study. Can J Anaesth. 2009;56:819–828.

American Sleep Association. Sleep Apnea Screening Questionnaire—‘STOP BANG’.

https://www.sleepassociation.org/sleep-apnea-screening-questionnaire-stop-bang. Accessed May 1,

2016.

Chia P et al. The association of pre-operative STOP-BANG scores with postoperative critical care admission.

Anaesthesia. 2013;68(9):950–952.

The Joint Commission. National patient safety goals.

www.jointcommission.org/assets/1/6/2015_npsg_hap.pdf. Accessed May 1, 2016

Moulton LS et al. Pre-operative education prior to elective hip arthroplasty surgery improves postoperative

outcome. Int Orthop. 2015;39(8):1483–1486.

Ilfeld DM et al. Ambulatory continuous interscalene nerve bocks decrease the time to discharge readiness after

total shoulder arthroplasty: a randomized, triple-masked, placebo-controlled study. Anesthesiology. 2006;105:

999–1007.

American Society of Regional Anesthesia and Pain Medicine. Checklist for treatment of local anesthetic systemic

t o x i c i t y . www.asra.com/advisory-guidelines/article/3/checklist-for-treatment-of-local-anestheticsystemic-toxicity. Accessed June 13, 2016.

Aubrun F et al. Postoperative intravenous morphine titration. Br J Anaesth. 2012;108(2):193–201.

Gregori S et al. Morphine metabolism, transport and brain disposition. Metab Brain Dis 2012;27:1–5.

Macintyre PE et al. Opioids, ventilation and acute pain management. Anaesth Intensive Care. 2011;39:545–558.

Kilmas R, Mikus G. Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration:

a quantitative review of morphine, morphine-3-glucuronide, and morphine-6-glucuronide. Br J Anaesth.

2014;113(6):935–944.

Principles of Analgesic Use. 7th Edition Chicago, IL: American Pain Society, 2016.

Sarhill N et al. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer.

2001;9:84–96.

Murray A, Hagen N. Hydromorphone. J Pain Symptom Manag. 2005;29:S57–S66.

Trescott AM et al. Opioid pharmacology. Pain Physician. 2008;11:S113–S153.

Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults.

Anesthesiology. 1999;90:576–599.

Grass JA. Patient controlled analgesia. Anesth Analg. 2005;101:S44–S61.

Weber LM et al. Implementation of standard order sets for patient-controlled analgesia. Am J Health-Syst

Pharm. 2008;65:1184–1191.

Dahan A et al. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology.

2010;112:226–238.

Dowell D et al. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016; MMWR

Recomm Rep. 2016;65:1–50

Oscier CD, Milner QJW. Perioperative use of paracetamol. Anesthesia. 2009;64:65–72

Pogatzki-Zahn E et al. Nonopioid analgesics for postoperative pain management. Curr Opin Anesthesiol.

2014;27:513–519.

McCarthy GC et al. Impact of intravenous lidocaine infusion on postoperative analgesia and recovery from

surgery. A systematic review of randomized controlled trials. Drugs. 2010;70(9):1149–1163

Sun Y et al. Perioperative systemic lidocaine for postoperative analgesia and recovery after abdominalsurgery:a

meta-analysis of randomized controlled trials. Dis Colon Rectum. 2012;55(11):1183–1194.

Waterman BR et al. Low back pain in the United States: incidence and risk factors for presentation in the

emergency setting. Spine J. 2012;12(1):63–70.

Becker A et al. Low back pain in primary care: costs of care and prediction of future health care utilization. Spine

(Phila Pa 1976). 2010;35:1714–1720.

Hestbaek L et al. Low back pain: what is the long-term course? A review of studies of general patient

populations. Eur Spine J. 2003;12:149.

Gatchel RJ et al. Psychosocial differences between high risk acute vs. chronic low back pain patients. Pain Pract.

2008;8:91.

Katz JN. Lumbar disc disorders and low-back pain:socioeconomic factors and consequences. J Bone Joint Surg

Am. 2006;88(Suppl 2):21.

Clays E et al. The impact of psychosocial factors on low back pain. Longitudinal results from the Belstress study.

Spine (Phila Pa 1976). 2007;32:262.

Stewart WF et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA.

2003;290:2443.

Nijs J et al. Low back pain: guidelines for the clinical classification of predominant neuropathic, nociceptive, or

centralsensitization pain. Pain Physician. 2015;18(3):E333–E346.

Deyo RA, Weinstein JN. Low back pain. N EnglJ Med. 2001;344:363.

U.S. Agency for Health Care Policy and Research. Acute low back pain problems in adults: assessment and

treatment. Clin Pract Guidel Quick Ref Guide Clin. 1994;(14):iii–iv, 1–25

Koes BW et al. An updated overview of clinical guidelines for the management of non-specific low back pain in

primary care. Eur Spine J 2010;19:2075.

Schnitzer TJ et al. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment

of low back pain. J Pain Symptom Manag. 2004;28:72.

Roelofs PD et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008;

(1):CD000396.

Machado GC et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and

meta-analysis of randomized placebo controlled trials. BMJ 2015;350h:1225 1–12.

van Tulder MW et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;

(2):CD004252.

Chou R et al. Medications for acute and chronic low back pain: a review of the evidence for an American Pain

Society/American College of Physicians clinical practice guideline [published correction appears in Ann Intern

Med. 2008;148:247]. Ann Intern Med. 2007;147:505.

Vorsanger GJ et al. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid

Manag. 2008;4:87.

Hale ME et al. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a

randomized, double-blind, placebo-a nd active-controlled phase III study. J Pain. 2005;6:21.

Buynak R et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain:

results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin

Pharmacother. 2010;11:1787.

Deshpande A et al. Opioids for chronic low back pain. Cochrane Database Syst Rev. 2007;(3):CD004959.

doi:10.1002/14651858.CD004959.pub3.

Salerno SM et al. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med.

2002;162:19.

Staiger TO et al. Systematic review of antidepressants in the treatment of chronic low back pain. Spine (Phila Pa

1976). 2003;28:2540.

Skljarevski V et al. Duloxetine versus placebo in patients with chronic low back pain: a 12 week fixed-dose,

randomized, double-blind trial. J Pain 2010;11(12):1282–1290.

Yildirim K et al. Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life

quality. J Back Musculoskelet Rehabil. 2009;22:17.

Khoromi S et al. Topiramate in chronic lumbar radicular pain. J Pain. 2005;6:829.

Muehlbacher M et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind,

placebo-controlled study. Clin J Pain. 2006:22:526.

McBeth J et al. Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the

European Male Ageing Study. Ann Rheum Dis. 2010;69:1448.

Warner AE, Arnspiger SA. Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved

by treatment with vitamin D. J Clin Rheumatol. 2008;14:12.

Opioidrisk. Risk assessment tools. http://www.opioidrisk.com/node/774. Accessed May 1, 2016

Kessler RC et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey

Replication (NCS-R). JAMA. 2003;289:3095.

Currie SR, Wang J. More data on major depression as an antecedent risk factor for first onset of chronic back

pain. Psychol Med. 2005;35:1275.

Bair MJ et al. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433.

Chang V et al. Evidence-informed management of chronic low back pain with adjunctive analgesics. Spine J.

2008;8:21.

Malanga GA et al. Tizanidine is effective in the treatment of myofascial pain syndrome. Pain Physician.

2002;5(4):422–432.

Chaparro LE et al. Opioids compared to placebo or other treatments for chronic low back pain. Cochrane

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

Database of Syst Rev. 2013;(8):CD004959.

Gilron I et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind,

randomised, controlled crossover trial. Lancet. 2009;374:1252.

Gilron I et al. Morphine, gabapentin, or their combination for neuropathic pain. N EnglJ Med. 2005;352:1324.

Pain-Outlet Clinical Guide. Monitoring treatment: the 5 A’s. www.pain-outlet.info/5-as.html. Accessed May 1,

2016

Chou R et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low backpain: an evidencebased clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976). 2009;34:1066.

Hagen KB et al. The updated Cochrane review of bed rest for low back pain and sciatica. Spine (Phila Pa 1976).

2005;30:542

Cherkin DC et al. Effect of mindfulness based stress reduction vs cognitive behavioral therapy or usual care on

back pain and functional limitations in adults with chronic low back pain. JAMA 2016;215(12):1240–1249.

Insinga RP et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med.

2005;20:748.

Volpi A. Severe complications of herpes zoster. Herpes. 2007;14(Suppl 2):35A.

Lunn MPT et al. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of

Syst Rev. 2014;(1):CD007115.

Cymbalta® [package insert]. Indianapolis, IN: Lilly USA, LLC; 2015.

Moore RA et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst

Rev. 2014;(4):CD007938.

Dworkin RH et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.

Neurology. 2003;60:1274.

Wiffen PJ et al. Antiepileptic drugs for neuropathic pain and fibromyalgia—an overview of Cochrane reviews.

Cochrane Database Syst Rev. 2013;(11):CD010567.

Qutenza® [package insert]. Ardsley, NY: Acorda Therapeutics;2013.

Vinik AI et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of

tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care.

2014;37(8):2302–2309.

Dubinsky RM et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the

Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959.

Kong KH et al. Prevalence of chronic pain and its impact on health-related quality of life in stroke survivors.

Arch Phys Med Rehabil. 2004;85:35–40.

Klit H et al. Central post-stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol.

2009;8:857–868.

Kim JS. Pharmacological management of central post-stroke pain: practical guide. CNS Drugs. 2014;28:787–

797.

Leijon G et al. Central post-stroke pain—a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27–

36.

Vestergaard K et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology.

2001;56:184–90.

Vranken JH et al. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebocontrolled trial of a flexible-dose regimen. Pain. 2008;136:150–157.

Rowbotham MC et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med.

2003;348:1223–1232.

Sperber AD, Drossman DA. Functional abdominal pain syndrome: constant or frequently recurring abdominal

pain. Am J Gastroenterol. 2010;105:770.

Kim SE, Chang L. Overlap between functional GI disorders and other functional syndromes: what are the

underlying mechanisms. Neurogastroenterol Motil 2012;24:895–913.

Katz J, Rosenbloom, Fashier S. Chronic pain, psychopathology, and DSM-5 somatic symptom disorder. Can J

Psychiatry 2015;60(4):160–167.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington,

VA: American Psychiatric Publishing; 2013.

Egloff N et al. Hypersensitivity and hyperalgesia in somatoform pain disorders. General Hospital Psychiatry.

2014;36:284–290.

Lacasse A et al. Fibromyalgia-related costs and loss of productivity: a substantial societal burden. BMC

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

Musculoskelet Disord. 2016;17:168–176

Berger A et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract.

2007;61(9):1498–508.

Wolfe F et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and

measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600–610.

Hauser W et al. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with metaanalysis. Arthritis Care Res. 2011;63(6):808–820.

Staud R et al. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and

subjects with fibromyalgia syndrome. Pain. 2003;102:87–95.

Staud R et al. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input:

a randomized, double-blind, placebo-controlled study. Pain. 2009;145:96–104.

Staud R et al. Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients

compared to normal controls. Pain. 2004;110:689–696.

Fibromyalgia Impact Questionnaire. http://fiqrinfo.ipage.com/Original%20FIQ.pdf. Accessed May 22,

2016.

Carville DF et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome.

Ann Rheum Dis. 2008;67:536.

Häuser W et al. Management of fibromyalgia syndrome—an interdisciplinary evidence-based guideline. Ger

Med Sci. 2008;6:Doc14.

Mease PJ et al. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rheumatol. 2011;25:285–297.

Fitzcharles M et al. Fibromyalgia: evolving concepts over the past 2 decades. Can Med Assoc J.

2013;185(13):E645–E651.

Goldenberg DL et al. Management of fibromyalgia. JAMA. 2004;292(19):2388–2395.

Hauser W et al. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review

and meta-analysis. CNS Drugs 2012;26 (4):297–307.

Clauw DJ et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized,

double-blind, placebo-controlled, multiple-dose clinical trial [published corrections appear in Clin Ther.

2009;31:446; Clin Ther. 2009;31:1617]. Clin Ther. 2008;30:1988.

Russell IJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major

depressive disorder: results from a 6 month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain.

2008;136:432.

Mease PJ et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of

patients with fibromyalgia. J Rheumatol. 2008;35:502.

Arnold LM et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in

patients with fibromyalgia. J Pain. 2008;9:792.

Crofford LJ et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM):

a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419.

Arnold LM et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled,

multicenter trial. Arthritis Rheum. 2007;56:1336.

Häuser W et al. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia

syndrome. J Pain. 2010;11:505.

Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist,

in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52:2495.

Goldenberg DL et al. Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc. 2016;91(5):640–648.

Younger J et al. Low-dose naltrexone for the treatment of fibromyalgia findings of a small, randomized, doubleblind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum.

2013;65(2):529–538.

Bernardy K et al. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome—a systematic review and

meta-analysis of randomized controlled trials. J Rheumatol. 2010;37:1991.

Häuser W et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review

and meta-analysis of randomized controlled trials. Arthritis Res Ther. 2010;12:R79.

Bidonde J et al. Aquatic exercise training for fibromyalgia. Cochrane Database of Syst Rev. 2014;

(10):CD011336.

Luciano JV et al. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration

recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation

146.

147.

148.

149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

159.

160.

161.

162.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

alongside a 6-month randomized controlled trial. Arthritis Res Ther. 2014;16:451–468.

Clouse RE et al. Functional abdominal pain syndrome. Gastroenterology. 2006;130:1492.

Jackson JL et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a metaanalysis. Am J Med. 2000;108:65.

Drossman DA. Severe and refractory chronic abdominal pain: treatment strategies. Clin Gastroenterol Hepatol.

2008;6:978.

Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593.

Manchikanti L et al. American society of interventional pain physicians (ASIPP) guidelines for responsible opioid

prescribing in chronic non-cancer pain: part 2 guidance. Pain Physician. 2012;15:S67–S116.

Liebschutz JM et al. Clinical factors associated with prescription drug use disorder in urban primary care

patients with chronic pain. J Pain. 2010;11(11):1047–1055.

Wasan AD et al. Psychiatric history and psychological adjustment as risk factors for aberrant drug-related

behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307–315.

Jamison RN et al. Gender differences in risk factors for aberrant prescription opioid use. J Pain.

2010;11(4):312–320.

Chang YP, Compton P. Management of chronic pain with chronic opioid therapy in patient with substance use

disorders. Addict Sci Clin Pract. 2013;8:21. doi:10.1186/1940-0640-8-21.

Turk DC et al. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis.

Clin J Pain. 2008;24:497.

Fishbain DA et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic

therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidenced-based review.

Pain Med. 2008;9:444.

Substance Abuse and Mental Health Services Administration. Managing Chronic Pain in Adults With or in

Recovery from Substance Use Disorders. Treatment Improvement Protocol (TIP) Series 54. HHS Publication

No. (SMA)12-4671. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.

Belgrade MJ et al. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain.

2006;7:671–681.

Pedersen L et al. Long- or short-acting opioids for chronic non-malignant pain? A qualitative systematic review.

Acta Anaesthesiol Scand. 2014;58:390–401.

Gowing LR et al. Alpha2

-adrenergic agonists in opioid withdrawal. Addiction. 2002;97:49.

Turk DC et al. Psychological approaches in the treatment of chronic pain patients—when pills, scalpels and

needles are not enough. Can J Psychiatry. 2008;53:213.

Davis MP, Walsh D. Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat

Care. 2004;21:137.

van den Beuken-van Everdingen MH et al. Prevalence of pain in patients with cancer: a systematic review of

the past 40 years. Ann Oncol. 2007;18:1437.

Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international

collaborative study. Symptom Prevalence Group. J Pain Symptom Manag. 1996;12:3.

Swarm R, et al. Adult cancer pain: clinical practice guidelines. National Comprehensive Cancer Network. J Natl

Compr Canc Netw. 2013;11(8):992–1021.

Epstein JB et al. Pain caused by cancer of the head and neck and oral mucositis. In: Fishman SA et al, eds.

Bonica’s Management of Pain. 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2010

Pancari P, Mehra R. Systemic therapy for squamous cell carcinoma of the head and neck. Surg Oncol Clin N

Am. 2015;24:437–454.

Scarpace SL et al. Treatment of head and neck cancers: issues for clinical pharmacists. Pharmacotherapy.

2009;29:578.

Windebank AJ, Grisold W Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27.

World Health Organization. Cancer Pain Relief and Palliative Care. Report of a WHO Expert Committee

(WHO Technical Report Series, No. 804). Geneva, Switzerland: World Health Organization; 1990.

Burton AW et al. Transformation of acute cancer pain to chronic cancer pain syndromes. Support Oncol.

2012;10(3):89–95.

Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med. 2009;12:947.

Kadian® [package insert]. Parsippany, NJ: Actavis Pharma; 2014

McPherson ML. Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. Bethesda, MD:

American Society of Health-System Pharmacists; 2010.

175.

176.

177.

178.

179.

180.

181.

182.

183.

184.

185.

186.

187.

188.

189.

190.

Heit HA, Gourlay DL. Buprenorphine: new tricks with an old molecule for pain management. Clin J Pain.

2008;24:93.

Fentanyl. Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO: Wolters

Kluwer Health; 2016. Accessed May 9, 2016.

Breitbart W et al. An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. Oncology

(Williston Park). 2000;14:695.

Donner B et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients

with cancer pain. Pain 1996;64:527.

Portenoy RK, Ahmed E. Principles of opioid use in cancer pain. J Clin Oncol. 2014;32:1662–1670.

Transmucosal fentanyl. Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO:

Wolters Kluwer Health; 2016. Accessed May 9, 2016.

Dirix P et al. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer.

2006;107:2525.

Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust.

2000;173:536.

Chou R et al. Methadone Safety Guidelines. Methadone safety: a clinical practice guideline from the American

Pain Society and College of Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J

Pain. 2014;15(4):321–337

Krantz MJ et al. QTc intervalscreening in methadone treatment. Ann Intern Med. 2009;150:387.

Strickland JM. Palliative pharmacy care. Can J Hosp Pharm. 2010;63(1):56.

Meiri E et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for

delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23:533–543.

Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems; a clinical

review. JAMA. 2015;313(24):2474–2483.

Agarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial

results. Clin J Pain. 2012;29:162–171.

Russo EB, Hohmann AG. Role of cannabinoids in pain management. In: Deer TR,et al, eds. Comprehensive

Treatment of Chronic Pain by Medical, Interventional, and BehavioralApproaches: The American Academy of

Pain Medicine Textbook on Patient Management. New York, NY: Springer, 2012.

Whiting P et al. Cannabinoids for the medical use: a systematic review and meta-analysis. JAMA.

2015;313(24):2456–2473.

p. 1204

HOME MEDICATIONS IN THE INTENSIVE CARE UNIT

Medications used to treat chronic conditions are often administered in

the intensive care unit (ICU) as long as it does not provide harm to the

patient. The decision to continue or hold medications that cause bleeding

(e.g., warfarin, clopidogrel), have hemodynamic effects (e.g., blood

pressure medication), have hypoglycemic effects (e.g., diabetes

medications), and/or that can potentially interact with medications

administered in the ICU is made on an individual basis based on risk and

benefit.

Case 56-1 (Question 1),

Case 56-2 (Question 1)

PHARMACOKINETICS OVERVIEW AND DRUG SELECTION

Available pharmacokinetic data are often determined in healthy subjects.

Critically ill patients may have significant changes in all (ADME)

pharmacokinetic parameters. The clinician should be attuned to those

disease states most likely to induce alterations and to develop

appropriate monitoring and management strategies for specific

medications.

Case 56-3 (Questions 1–8)

PAIN, AGITATION, AND DELERIUM

Pain, agitation, and delirium commonly occur in critically ill patients for a

variety of reasons. Clinicians should vigilantly assess patients for pain

and provide adequate analgesia. They should attempt to identify and

address underlying conditions leading to agitation and delirium.

Case 56-4 (Questions 1, 2),

Case 56-5 (Question 1),

Case 56-6 (Question 1),

Table 56-1

Opioids are the most commonly used analgesics in the ICU. Patientspecific characteristics and differences between hydromorphone,

fentanyl, and morphine should be considered when designing the optimal

analgesic regimen for a patient.

Case 56-4 (Question 3),